Company research
AMARIN CORP PLC\UK
CIK 897448Updated Oct 29, 2026
SecurityAMRN · NASDAQ · equity
Name history
AMARIN CORP PLC\UK · through Oct 28, 2026AMARIN PHARMACEUTICALS PLC · through Jul 13, 2000ETHICAL HOLDINGS PLC · through Jan 28, 1998
AMRN price & chart
Loading TradingView…
NASDAQ:AMRN on TradingView ↗About the company
At the Heart of Amarin Corporation is a singular focus on advancing cardiovascular disease prevention worldwide. Our flagship oral prescription therapy, VASCEPA® (icosapent ethyl or IPE), is the U.S. market leader across all available IPE products and has been prescribed more than 32 million times globally. Through our independent U.S. commercial operations and global commercial partnerships, Amarin supports access to VASCEPA/VAZKEPA® across nearly 100 markets worldwide. For more information, visit www.amarincorp.com and follow Amarin on LinkedIn, X, Facebook. To be added to the Company's email list and receive news directly, please visit https://investors.amarincorp.com/email-alerts.
In the news
American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction ↗
Seeking Alpha
Amarin expects U.S. volumes to remain stable through 2026 while Europe demand rises 68% ↗
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript ↗
At a glance: stocks gapping up premarket ↗
SEC disclosures
AMARIN CORP PLC\UK files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13D/A - filed by Sarissa Capital Management LP regarding AMARIN CORP PLC\UK
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 659,814,000Source | 750,615,000Source | 624,363,000Source | 670,126,000Source | 799,855,000Source | 645,764,000Source | 655,677,000Source | 790,013,000Source | 670,775,000Source | 685,349,000Source | 831,684,000Source | 886,179,000Source |
| Property, Plant and Equipment, NetUSD | 13,000Source | 24,000Source | — | 14,000Source | 49,000Source | — | 15,000Source | 81,000Source | 12,000Source | 16,000Source | 114,000Source | 874,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 122,802,000Source | 156,944,000Source | 143,558,000Source | 147,877,000Source | 215,924,000Source | 131,063,000Source | 119,524,000Source | 213,944,000Source | 134,660,000Source | 121,038,000Source | 199,252,000Source | 217,666,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 127,309,000Source | 112,642,000Source | 92,917,000Source | 119,130,000Source | 123,691,000Source | 108,051,000Source | 106,734,000Source | 115,806,000Source | 126,832,000Source | 122,279,000Source | 133,563,000Source | 130,990,000Source |
| Inventory, NetUSD | 184,703,000Source | 224,000,000Source | 164,073,000Source | 171,244,000Source | 239,408,000Source | 183,585,000Source | 159,490,000Source | 255,280,000Source | 195,910,000Source | 166,048,000Source | 258,616,000Source | 228,732,000Source |
| Assets, CurrentUSD | 628,334,000Source | 650,216,000Source | 602,758,000Source | 606,819,000Source | 701,839,000Source | 626,016,000Source | 573,061,000Source | 687,932,000Source | 649,882,000Source | 595,399,000Source | 724,981,000Source | 689,098,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 29,434,000Source | 7,316,000Source | 30,918,000Source | 17,441,000Source | 31,552,000Source | 26,357,000Source | 24,750,000Source | 8,142,000Source | 24,350,000Source | 12,552,000Source | 11,618,000Source | 19,492,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,186,000Source | 7,984,000Source | 5,564,000Source | 7,640,000Source | 7,540,000Source | 6,010,000Source | 8,363,000Source | 7,876,000Source | 6,461,000Source | 7,592,000Source | 8,310,000Source | 9,074,000Source |
| Other Assets, NoncurrentUSD | 1,109,000Source | 1,250,000Source | 3,949,000Source | 1,135,000Source | 1,287,000Source | 1,010,000Source | 1,174,000Source | 1,324,000Source | 1,055,000Source | 1,213,000Source | 1,360,000Source | 458,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 200,920,000Source | 219,240,000Source | 180,747,000Source | 205,202,000Source | 247,976,000Source | 196,351,000Source | 181,990,000Source | 244,077,000Source | 211,494,000Source | 199,173,000Source | 279,587,000Source | 290,846,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 310,019,000Source | 305,202,000Source | 314,531,000Source | 309,421,000Source | 305,046,000Source | 314,062,000Source | 308,152,000Source | 304,742,000Source | 310,184,000Source | 305,298,000Source | 302,756,000Source | 299,002,000Source |
| Additional Paid in CapitalUSD | 1,922,351,000Source | 1,911,445,000Source | 1,923,885,000Source | 1,920,993,000Source | 1,906,903,000Source | 1,922,254,000Source | 1,916,223,000Source | 1,902,698,000Source | 1,923,801,000Source | 1,914,750,000Source | 1,899,456,000Source | 1,885,352,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,706,120,000Source | -1,619,928,000Source | -1,725,506,000Source | -1,698,382,000Source | -1,594,794,000Source | -1,717,856,000Source | -1,684,243,000Source | -1,596,316,000Source | -1,707,344,000Source | -1,668,546,000Source | -1,586,363,000Source | -1,527,251,000Source |
| Stockholders' Equity Attributable to ParentUSD | 458,894,000Source | 531,375,000Source | 443,616,000Source | 464,924,000Source | 551,879,000Source | 449,413,000Source | 473,687,000Source | 545,936,000Source | 459,281,000Source | 486,176,000Source | 552,097,000Source | 595,333,000Source |
| Liabilities and EquityUSD | 659,814,000Source | 750,615,000Source | 624,363,000Source | 670,126,000Source | 799,855,000Source | 645,764,000Source | 655,677,000Source | 790,013,000Source | 670,775,000Source | 685,349,000Source | 831,684,000Source | 886,179,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 182,233,000Source | 201,554,000Source | 164,195,000Source | 185,946,000Source | 230,542,000Source | 179,644,000Source | 162,408,000Source | 224,381,000Source | 194,459,000Source | 179,949,000Source | 259,277,000Source | 259,479,000Source |
| Operating Lease, Liability, CurrentUSD | 2,301,000Source | 1,938,000Source | 1,920,000Source | 2,216,000Source | 1,620,000Source | 2,116,000Source | 2,400,000Source | 1,725,000Source | 2,148,000Source | 1,951,000Source | 1,870,000Source | 1,566,000Source |
| Accounts Payable, CurrentUSD | 36,712,000Source | 40,507,000Source | 18,796,000Source | 44,711,000Source | 54,383,000Source | 48,153,000Source | 45,661,000Source | 67,600,000Source | 45,355,000Source | 40,366,000Source | 52,762,000Source | 64,602,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,731,000Source | 8,215,000Source | 5,255,000Source | 7,338,000Source | 8,099,000Source | 5,585,000Source | 7,940,000Source | 8,389,000Source | 6,080,000Source | 7,723,000Source | 8,737,000Source | 10,015,000Source |
| Other Liabilities, NoncurrentUSD | 11,956,000Source | 9,471,000Source | 11,297,000Source | 11,918,000Source | 9,335,000Source | 11,122,000Source | 11,642,000Source | 9,199,000Source | 10,955,000Source | 11,501,000Source | 9,064,000Source | 8,205,000Source |
| Additional Financial Items | ||||||||||||
| Short-term InvestmentsUSD | 163,785,000Source | 148,788,000Source | 171,091,000Source | 150,827,000Source | 90,739,000Source | 176,759,000Source | 162,263,000Source | 94,235,000Source | 167,929,000Source | 173,182,000Source | 121,407,000Source | 91,695,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -10,512,000Source | -15,697,000Source | -38,798,000Source | -82,183,000Source | -59,112,000Source | -105,803,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,331,000Source | 4,327,000Source | 13,937,000Source | 17,705,000Source | 15,646,000Source | 26,213,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -18,781,000Source | -15,545,000Source | 4,553,000Source | -11,284,000Source | 2,573,000Source | -32,663,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -12,325,000Source | -13,894,000Source | -34,878,000Source | -105,443,000Source | -56,121,000Source | 36,422,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 6,388,000Source | -12,459,000Source | 6,728,000Source | -31,020,000Source | 6,880,000Source | -180,092,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -8,298,000Source | 12,064,000Source | 8,829,000Source | -45,976,000Source | -25,522,000Source | 175,288,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 1,687,000Source | 1,119,000Source | 2,174,000Source | 1,574,000Source | 1,982,000Source | 1,044,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -1,687,000Source | -1,119,000Source | -2,034,000Source | -1,443,000Source | 230,000Source | -379,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,597,000Source | -1,514,000Source | 13,523,000Source | -78,439,000Source | -18,412,000Source | -5,183,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 2,331,000Source | 22,000Source | 1,000,000Source | -3,982,000Source | -2,367,000Source | -1,782,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 637,000Source | 729,000Source | 3,024,000Source | 2,915,000Source | 2,805,000Source | 2,545,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | 100,000Source | 200,000Source | 600,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | -700,000Source | 800,000Source | -2,600,000Source | -700,000Source |
| General and Administrative ExpenseUSD | — | — | 9,012,000Source | 9,693,000Source | 13,990,000Source | 14,524,000Source | 11,273,000Source | 8,648,000Source | 43,752,000Source | 38,290,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | -377,000Source | 3,605,000Source | -219,000Source | 689,000Source | 1,789,000Source | 2,067,000Source | 2,750,000Source | 4,983,000Source | 5,442,000Source | 1,998,000Source |
| Investment Income, InterestUSD | — | — | — | — | 3,050,000Source | 2,620,000Source | 2,423,000Source | 2,872,000Source | 10,853,000Source | 13,403,000Source | 11,863,000Source | 2,819,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,738,000Source | -25,134,000Source | -7,650,000Source | -14,139,000Source | -10,512,000Source | -15,697,000Source | -38,798,000Source | -82,183,000Source | -59,112,000Source | -105,803,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,738,000Source | -25,134,000Source | -7,650,000Source | -14,139,000Source | -10,512,000Source | -15,697,000Source | -38,798,000Source | -82,183,000Source | -59,112,000Source | — |
| Operating ExpensesUSD | — | — | 33,311,000Source | 41,444,000Source | 26,999,000Source | 66,347,000Source | 29,103,000Source | 41,885,000Source | 171,038,000Source | 173,179,000Source | 233,129,000Source | 348,353,000Source |
| Operating Lease, ExpenseUSD | — | — | 800,000Source | 800,000Source | 700,000Source | 900,000Source | 700,000Source | 800,000Source | 2,700,000Source | 2,900,000Source | 3,200,000Source | 2,800,000Source |
| Operating Lease, Lease IncomeUSD | — | — | 249,000Source | 249,000Source | 249,000Source | 249,000Source | 249,000Source | 249,000Source | 995,000Source | 995,000Source | 912,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 205,000Source | 265,000Source | 1,091,000Source | -85,000Source | 188,000Source | 253,000Source | 3,276,000Source | 1,201,000Source | 2,063,000Source | -740,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 0Source | 10,000Source | 1,882,000Source | 60,000Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | 4,400,000Source | 7,300,000Source | 6,800,000Source | 14,800,000Source |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | — | — | — | — | — |
| Restructuring Costs | — | — | —Source | — | —Source | —Source | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 49,670,000Source | 42,298,000Source | 42,211,000Source | 72,741,000Source | 45,132,000Source | 42,017,000Source | 213,646,000Source | 228,614,000Source | 306,911,000Source | 369,193,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 19,697,000Source | 36,904,000Source | 22,186,000Source | 38,673,000Source | 21,115,000Source | 36,573,000Source | 115,003,000Source | 152,310,000Source | 199,938,000Source | 304,416,000Source |
| Operating Income (Loss)USD | — | — | -11,103,000Source | -25,168,000Source | -12,010,000Source | -15,985,000Source | -11,334,000Source | -16,755,000Source | -50,170,000Source | -91,797,000Source | -67,588,000Source | -105,869,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 205,000Source | 265,000Source | 1,091,000Source | -85,000Source | 188,000Source | 253,000Source | 3,276,000Source | 1,201,000Source | 2,063,000Source | -740,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -8,115,000Source | -21,529,000Source | -7,869,000Source | -13,450,000Source | -8,723,000Source | -13,630,000Source | -36,048,000Source | -77,200,000Source | -53,670,000Source | -103,805,000Source |
| Income Tax Expense (Benefit)USD | — | — | -377,000Source | 3,605,000Source | -219,000Source | 689,000Source | 1,789,000Source | 2,067,000Source | 2,750,000Source | 4,983,000Source | 5,442,000Source | 1,998,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,738,000Source | -25,134,000Source | -7,650,000Source | -14,139,000Source | -10,512,000Source | -15,697,000Source | -38,798,000Source | -82,183,000Source | -59,112,000Source | -105,803,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.02Source | -0.06Source | -0.02Source | -0.03Source | -0.03Source | -0.04Source | -0.09Source | -0.2Source | -0.15Source | -0.26Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.02Source | -0.06Source | -0.02Source | -0.03Source | -0.03Source | -0.04Source | -0.09Source | -0.2Source | -0.15Source | -0.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 415,531,000Source | 411,150,000Source | 416,444,000Source | 414,477,000Source | 419,054,000Source | 413,422,000Source | 414,984,000Source | 410,937,000Source | 407,655,000Source | 401,155,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 415,531,000Source | 411,150,000Source | 416,444,000Source | 414,477,000Source | 419,054,000Source | 413,422,000Source | 414,984,000Source | 410,937,000Source | 407,655,000Source | 401,155,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 637,000Source | 729,000Source | 3,024,000Source | 2,915,000Source | 2,805,000Source | 2,545,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,750,000Source | 4,983,000Source | 5,442,000Source | 1,998,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | -700,000Source | 800,000Source | -2,600,000Source | -700,000Source |
| General and Administrative ExpenseUSD | — | — | 9,012,000Source | 9,693,000Source | 13,990,000Source | 14,524,000Source | 11,273,000Source | 8,648,000Source | 43,752,000Source | 38,290,000Source | — | — |
| Gross ProfitUSD | — | — | 22,208,000Source | 16,276,000Source | 14,989,000Source | 50,362,000Source | 17,769,000Source | 25,130,000Source | 120,868,000Source | 81,382,000Source | 165,541,000Source | 242,484,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 24,538,000Source | -5,284,000Source | 15,881,000Source | 5,358,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 7,000Source | 7,000Source | 8,000Source | 15,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 2,783,000Source | 3,374,000Source | 3,050,000Source | 2,620,000Source | 2,423,000Source | 2,872,000Source | 10,853,000Source | 13,403,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | 3,050,000Source | 2,620,000Source | 2,423,000Source | 2,872,000Source | 10,853,000Source | 13,403,000Source | 11,863,000Source | 2,819,000Source |
| Lease IncomeUSD | — | — | 263,000Source | 264,000Source | 261,000Source | 263,000Source | 262,000Source | 264,000Source | 1,051,000Source | 1,057,000Source | 912,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,738,000Source | -25,134,000Source | -7,650,000Source | -14,139,000Source | -10,512,000Source | -15,697,000Source | -38,798,000Source | -82,183,000Source | -59,112,000Source | — |
| Operating ExpensesUSD | — | — | 33,311,000Source | 41,444,000Source | 26,999,000Source | 66,347,000Source | 29,103,000Source | 41,885,000Source | 171,038,000Source | 173,179,000Source | 233,129,000Source | 348,353,000Source |
| Operating Lease, ExpenseUSD | — | — | 800,000Source | 800,000Source | 700,000Source | 900,000Source | 700,000Source | 800,000Source | 2,700,000Source | 2,900,000Source | 3,200,000Source | 2,800,000Source |
| Operating Lease, Lease IncomeUSD | — | — | 249,000Source | 249,000Source | 249,000Source | 249,000Source | 249,000Source | 249,000Source | 995,000Source | 995,000Source | 912,000Source | — |
| Research and Development ExpenseUSD | — | — | 4,208,000Source | 4,540,000Source | 4,773,000Source | 4,915,000Source | 4,665,000Source | 5,312,000Source | 19,806,000Source | 20,869,000Source | 22,219,000Source | 30,411,000Source |
| Selling ExpenseUSD | — | — | 2,722,000Source | 9,107,000Source | 1,785,000Source | 8,476,000Source | 2,554,000Source | 7,384,000Source | 21,512,000Source | 40,150,000Source | — | — |
| Restructuring Costs | — | — | —Source | — | —Source | —Source | —Source | — | — | — | — | — |
Filing attachments
amrn-ex99_1.htm · 8-K · 2026-10-28
Exhibit 99.1 Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income DUBLIN, Ireland and BRIDGEWATER, N.J., October 28, 2026 -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued …
Read attachment ↗amrn-ex99_1.htm · 8-K · 2026-07-29
EX-99.1 2 amrn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Ca…
Read attachment ↗amrn-ex99_1.htm · 8-K · 2026-04-29
EX-99.1 2 amrn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amarin Reports 2026 First Quarter Financial Results Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 -…
Read attachment ↗amrn-ex4_4.htm · 10-K · 2026-03-02
Exhibit 4.4 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Description of Ordinary Shares In the following summary, a “shareholder” is the person registered in our register of members as the holder of the relevant securities, including ordinary shares that have been deposited in our American Depositary Share, or ADS, facility. Dividends Holders of ordinary shares are entitled to receive such dividends as may be declared by the…
Read attachment ↗amrn-ex99_1.htm · 8-K · 2026-02-25
EX-99.1 2 amrn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amarin Reports Fourth Quarter and Full Year 2025 Financial Results Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent et…
Read attachment ↗amrn-ex99_1.htm · 8-K · 2026-01-08
Exhibit 99.1 AMARIN ANNOUNCES PRELIMINARY 2025 FINANCIAL HIGHLIGHTS AND OPERATIONAL ACCOMPLISHMENTS, INCLUDING ACHIEVING POSITIVE CASH FLOW; COMPANY WELL POSITIONED TO CAPTURE GLOBAL GROWTH OPPORTUNITIES U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Completed Transition to Fully Partnered Model Across All International Markets DUBLIN, Ireland and BRIDGEWATER, N.J., January 8, 2026 - Amarin Corporation plc (NASDAQ:AMRN), a company advancing the sci…
Read attachment ↗